A Phase 1 Study of TAK-007 in Refractory Lupus Nephritis

Withdrawn Phase 1 NCT06377228

Study Description

A Study to Test the Safety and Effectiveness of a New Treatment (TAK-007) for Adults with Lupus Nephritis that has not Responded to Other Treatments

Study Details

Registry ID:: NCT06377228
Conditions:: Refractory Lupus Nephritis, Refractory Systemic Sclerosis
Phase:: Phase 1
Start Date:: June 13, 2025
Age Range:: 18–75 years
Healthy Volunteers:: No

Study Locations (4 sites)

University of Rochester
Rochester, New YorkUnited States, United States
University of Michigan
Ann Arbor, MichiganUnited States, United States
University of Texas Health Science Center
Houston, TexasUnited States, United States
UT Health Houston
Houston, TexasUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →